How We Invest

13F FILER • PAUL MARSHALL

Marshall Wace

Paul Marshall — MARSHALL WACE, LLP

No writing by this manager has been read and indexed yet, so this page carries the filings only. Holdings come straight from the Form 13F-HR on EDGAR.

3103

Positions

$126.7B

Reported Value

37.7%

In Top 10

—

Claims Indexed

Largest reported positions

MARSHALL WACE, LLP • CIK 0001318757 • 2026-06-30 • FILED 2026-08-13

WHAT CHANGED THIS QUARTER

In its Q2 2026 13F, filed Aug 13, 2026, Marshall Wace reported 3,103 positions worth $117.9B in US-listed stock. With 3,103 positions and only 37.7% in the ten largest, this is a diffuse book, where single lines are inventory rather than convictions.

It opened 784 new positions, and exited 811, the largest stock exits being Merck & Co ($334.2M last quarter), Sempra ($132.0M last quarter) and Insulet Corp ($127.3M last quarter).

Among positions it already held, the biggest increases by share count were Abbvie Inc (+281758%), Jp Morgan Chase (+11481%) and Qualcomm Inc (+10157%), and the biggest cuts were Sandisk Corp (−63%), Broadcom Inc (−52%) and Applied Material (−48%).

Largest reported positions, quarter ended 2026-06-30
IssuerValueWeightShares QoQ
ISHARES-S&P 500$29.8B23.5%+52%
SPDR PORTFOLIO L$4.1B3.3%-6%
APPLE INC$2.6B2.1%+8%
AMAZON.COM INC$2.3B1.8%+8%
ADV MICRO DEVICE$2.3B1.8%+3%
NVIDIA CORP$1.7B1.4%-37%
MICRON TECH$1.6B1.2%+50%
MICROSOFT CORP$1.2B1.0%-1%
COSTCO WHOLESALE$1.1B0.9%+345%
MORGAN STANLEY$971.8M0.8%+11%
TESLA INC$920.4M0.7%+5%
TAIWAN SEMIC-ADR$864.6M0.7%-19%
ALPHABET INC-A$790.1M0.6%-30%
HILTON WORLDWIDE$766.4M0.6%-8%
UNITEDHEALTH GRP$761.9M0.6%+30%
JOHNSON&JOHNSON$759.3M0.6%+26%
ABBVIE INC$752.5M0.6%+281758%
BANK OF AMERICA$711.3M0.6%+582%
COCA-COLA CO/THE$669.7M0.5%+47%
JP MORGAN CHASE$647.5M0.5%+11481%

20 of 3,103 positions. 6.5% of reported value is options, where the figure is the notional value of the underlying rather than money spent. $631.5M of the reported value is Section 13(f) debt — convertible notes and the like — which the form covers alongside equities. A 13F covers long US-listed positions at a quarter end only — no shorts, leverage, cash, ordinary bonds or private holdings — and is 45 days old on publication.

EXITS

  • Merck & Co$334.2M last quarter
  • Sempra$132.0M last quarter
  • Insulet Corp$127.3M last quarter
  • Rocket Lab Corp$120.8M last quarter
  • Kimberly-Clark$114.1M last quarter

QUESTIONS PEOPLE ASK

What are Marshall Wace's largest holdings?

OPEN
As of Jun 30, 2026, the three largest stock positions are Ishares-S&P 500 (23.5%), Spdr Portfolio L (3.3%) and Apple Inc (2.1%). With 3,103 positions and only 37.7% in the ten largest, this is a diffuse book, where single lines are inventory rather than convictions.

How big is Marshall Wace's 13F portfolio?

OPEN
The Q2 2026 13F, filed Aug 13, 2026, reports 3,103 positions worth $126.7B. The ten largest make up 37.7% of it. 6.5% of that value is options, reported at the notional value of the underlying rather than money spent.

What did Marshall Wace buy and sell in Q2 2026?

OPEN
It opened 784 new positions, and exited 811, the largest stock exits being Merck & Co ($334.2M last quarter), Sempra ($132.0M last quarter) and Insulet Corp ($127.3M last quarter). Among positions it already held, the biggest increases by share count were Abbvie Inc (+281758%), Jp Morgan Chase (+11481%) and Qualcomm Inc (+10157%), and the biggest cuts were Sandisk Corp (−63%), Broadcom Inc (−52%) and Applied Material (−48%).

When is Marshall Wace's next 13F due?

OPEN
The Q3 2026 13F is due Nov 16, 2026. Forty-five days after the quarter ends is November 14, 2026 (Saturday), so the deadline moves to the next business day. Paul Marshall's filing usually lands close to the deadline.

Filers with overlapping books